Figure 3 from Ammonia Suppresses the Antitumor Activity of Natural Killer Cells and T Cells by Decreasing Mature Perforin by Joanna Domagala (21643925)

Inhibition of IL-17A at tumor sites decreases the intratumoral microvessel density. by Keiji Hayata (277090)

“…Data are representative of two independent experiments. Data are presented as means ± SE (<i>n</i> = 5). …”

Conditional depletion of RPS0A significantly decreases translation initiation rates. by Tomáš Kouba (153719)

UGGT activity decreases in <i>uggt-1(RNAi)</i> worms but no decrease was observed in <i>uggt-2 (RNAi)</i> worms. by Lucila I. Buzzi (198284)

Table 5_Road transportation is associated with decreased intestinal motility in horses.docx by Sharanne L. Raidal (3097719)

“…Horses with high heart rates, high sweat scores or abnormal demeanour on arrival demonstrated decreased intestinal motility. Salivary cortisol concentrations increased after transportation (mean difference, 95% CI, for T0 vs T1 was 1.66, 1.09−2.53 nmol/L) and were inversely associated with intestinal motility. …”

Administration of anti-CD25 antibody decreases the early and late organ fungal burdens of resistant and susceptible mice. by Maíra Felonato (296591)

Quercetin decreases proliferation (A) and induces apoptosis (B) in cultured PASMC from control rats. by Daniel Morales-Cano (668199)

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects: